<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525665</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_PETRA</org_study_id>
    <nct_id>NCT03525665</nct_id>
  </id_info>
  <brief_title>Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression</brief_title>
  <official_title>Study on the Role of FDG-PET in Patients With Follicular Lymphoma at Time of Relapse/Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a retrospective analysis of patients with relapsed/refractory FL
      identified by the hematological centers of Italy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study does not require any intervention on the patient, but it involves the simple
      collection of data that are already present in the medical record. Since this is a
      retrospective study, it will not require further analysis or diagnostic investigations than
      those already made.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>24 months</time_frame>
    <description>Progression free survival from time of relapse/progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <enrollment type="Actual">175</enrollment>
  <condition>Follicular Lymphoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metabolic activity measured by FDG-PET</intervention_name>
    <description>To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with relapsed/refractory FL identified by the hematological centers of Italy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with initial diagnosis of follicular lymphoma since 2001

          -  Histological confirmation of follicular lymphoma, grade I, II, III according to WHO
             2008 classification, at the time of initial diagnosis

          -  Systemic first-line treatment with immuno-chemotherapy

          -  PET availability at the time of response after first-line treatment (optional)

          -  Clinical and radiological evidence of FL relapse or progression

          -  Histological confirmation of relapse (strongly recommended)

          -  PET availability of at the time of relapse/progression and images available for
             central assessment

          -  Availability of clinical, laboratory and therapeutic treatment data at the time of
             initial diagnosis and relapse/progression

          -  Follow up of at least 12 months after relapse/progression

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Luminari</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ematologia - AO Arcispedale Santa Maria Nuova - IRCCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.O.C. Ematologia Ospedale &quot;San Nicola Pellegrino&quot; ASL BAT</name>
      <address>
        <city>Trani</city>
        <state>BT</state>
        <zip>70031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Gerardo Di Monza</name>
      <address>
        <city>Monza</city>
        <state>Monza Brianza</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CROB</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>Potenza</state>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico &quot;A. Gemelli&quot;</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emat Univ - Città della salute e della scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOS Ematologia Ospedale C. Massaia</name>
      <address>
        <city>Asti</city>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili di Brescia - Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnas Nuovo Ospedale Garibaldi Nesima - U.O.C. Ematologia</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Ospedale Civile di Legnano</name>
      <address>
        <city>Legnano</city>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Madonna delle Grazie</name>
      <address>
        <city>Matera</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca` Granda-Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Modena - Università degli studi</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità di Novara - SCDU Ematologia</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera V.Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Centro Trapianto Midollo Osseo - Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.R. &quot;San Carlo&quot; - U.O. Ematologia</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Bianchi Melacrino Morelli UO Ematologia</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Arcispedale S.Maria Nuova Ematologia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico - &quot;Area Ematologia Trapianto Cellule Staminali Medicina Trasfusionale e Terapia cellulare&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl Ta Di Taranto</name>
      <address>
        <city>Taranto</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S. Maria&quot;</name>
      <address>
        <city>Terni</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. C. Panico</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Maria Della Misericordia Di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicular lymphoma</keyword>
  <keyword>FDG-PET</keyword>
  <keyword>Relapse/progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

